Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    SPG302

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Spinogenix Announces WHO Approval of 'tazbentetol'
    Spinogenix Announces WHO Approval of 'tazbentetol'

    01 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-announces-world-health-organization-approval-of-tazbentetol-as-international-non-proprietary-name-for-spg302-302628935.html

    PR NEWSWIRE
    01 Dec 2025
    Share Share
    Spinogenix Unveils Phase 2A Results For SPG302, In ALS
    Spinogenix Unveils Phase 2A Results For SPG302, In ALS

    04 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-presents-topline-phase-2a-clinical-trial-results-for-spg302-a-first-in-class-als-treatment-302603975.html

    PR NEWSWIRE
    04 Nov 2025
    Share Share
    Spinogenix Reveals Spg302's Neuroprotective Effects In Glaucoma
    Spinogenix Reveals Spg302's Neuroprotective Effects In Glaucoma

    16 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/spinogenix-announces-publication-of-preclinical-study-demonstrating-neuroprotective-effects-of-spg302-in-a-model-of-glaucoma-302586055.html

    PR NEWSWIRE
    16 Oct 2025
    Share Share
    Spinogenix Gets FDA IND Clearance For ALS Therapy SPG302
    Spinogenix Gets FDA IND Clearance For ALS Therapy SPG302

    29 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/29/2889788/0/en/Spinogenix-Announces-FDA-Clearance-of-IND-Application-for-SPG302-a-Novel-Therapy-for-the-Treatment-of-ALS.html

    GLOBENEWSWIRE
    29 May 2024
    Share Share